Literature DB >> 31898963

Prognostic Value of Serum Uric Acid in Hospitalized Heart Failure Patients With Preserved Ejection Fraction (from the Japanese Nationwide Multicenter Registry).

Yuta Kobayashi1, Kazunori Omote1, Toshiyuki Nagai2, Kiwamu Kamiya1, Takao Konishi1, Takuma Sato1, Yoshiya Kato1, Hirokazu Komoriyama1, Shingo Tsujinaga1, Hiroyuki Iwano1, Kazuhiro Yamamoto3, Tsutomu Yoshikawa4, Yoshihiko Saito5, Toshihisa Anzai1.   

Abstract

Elevated serum uric acid (UA) is associated with an increased risk of cardiovascular disease and worse clinical outcome in patients with cardiovascular disease. Nevertheless, the prognostic value of serum UA level in hospitalized heart failure patients with preserved ejection fraction (HFpEF) has not been fully elucidated. The aim of this study was to investigate whether serum UA level on admission could be associated with subsequent mortality in hospitalized patients with HFpEF. We examined 516 consecutive hospitalized HFpEF (left ventricular ejection fraction ≥50%) patients with decompensated heart failure from our HFpEF-specific multicenter registry who had serum UA data on admission. The primary outcome of interest was all-cause death. During a median follow-up period of 749 (interquartile range 540 to 831) days, 90 (17%) patients died. Higher serum UA level was significantly related to increased incidence of all-cause death (p = 0.016). In addition, patients with higher serum UA (≥6.6 mg/dl, median) and plasma B-type natriuretic peptide (≥401.2 pg/ml, median) levels had the highest incidence of all-cause death in the groups (p = 0.002). In multivariable Cox regression analysis, serum UA was an independent determinant of mortality (hazards ratio 1.23, 95% confidence interval 1.10 to 1.39) even after adjustment for prespecified confounders, renal function and the use of diuretics before admission. In conclusions, higher admission serum UA was an independent determinant of mortality in hospitalized HFpEF patients. Our findings indicate the importance of assessing admission serum UA level for further risk stratification in hospitalized patients with HFpEF.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31898963     DOI: 10.1016/j.amjcard.2019.12.003

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  2 in total

Review 1.  Hyperuricemia and the Risk of Heart Failure: Pathophysiology and Therapeutic Implications.

Authors:  Ke Si; Chijing Wei; Lili Xu; Yue Zhou; Wenshan Lv; Bingzi Dong; Zhongchao Wang; Yajing Huang; Yangang Wang; Ying Chen
Journal:  Front Endocrinol (Lausanne)       Date:  2021-11-12       Impact factor: 5.555

2.  Time-to-event prediction analysis of patients with chronic heart failure comorbid with atrial fibrillation: a LightGBM model.

Authors:  Chu Zheng; Jing Tian; Ke Wang; Linai Han; Hong Yang; Jia Ren; Chenhao Li; Qing Zhang; Qinghua Han; Yanbo Zhang
Journal:  BMC Cardiovasc Disord       Date:  2021-08-04       Impact factor: 2.298

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.